Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 49Nasopharyngeal Carcinoma 46Neoplasms 43Multiple Myeloma 41Stomach Neoplasms 34Lung Neoplasms 32Ovarian Neoplasms 31Neoplasm Metastasis 31Leukemia, Myeloid, Acute 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Triple Negative Breast Neoplasms 25Recurrence 25Pancreatic Neoplasms 25Small Cell Lung Carcinoma 21Esophageal Neoplasms 21Brain Neoplasms 21Uterine Cervical Neoplasms 20Colonic Neoplasms 20Lymphoma, Large B-Cell, Diffuse 18Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

tislelizumab 1Pemetrexed 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Advanced Non-squamous Non-small-cell Lung Cancer × Clear all
NCT06416410 2025-04-04

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Allist Pharmaceuticals, Inc.

Phase 3 Recruiting
392 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡